Role of the LKB1/AMPK pathway in tumor invasion and metastasis of cancer cells (Review)

Oncology Reports

Volumn 34, Issue 6, 2015, Pages 2821-2826

  Li, Nianshuang ^a   Huang, Deqiang ^a   Lu, Nonghua ^a   Luo, Lingyu ^a  

^a NANCHANG UNIVERSITY   (China)

Author keywords

AMP activated protein kinase; Liver kinase B1; Metastasis; TGF signal transduction; Tumor invasion

Indexed keywords

ADENYLATE KINASE; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE LKB1; TRANSFORMING GROWTH FACTOR BETA; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; PROTEIN SERINE THREONINE KINASE; STK11 PROTEIN, HUMAN;

CANCER CELL; CANCER GROWTH; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; ENERGY METABOLISM; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; INTRACELLULAR SIGNALING; METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; TUMOR INVASION; BIOSYNTHESIS; CARCINOMA; CELL MOTION; GENETICS; PATHOLOGY; PEUTZ JEGHERS SYNDROME; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

AMP-ACTIVATED PROTEIN KINASES; CARCINOMA; CELL MOVEMENT; CELL PROLIFERATION; GENES, TUMOR SUPPRESSOR; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PEUTZ-JEGHERS SYNDROME; PROTEIN-SERINE-THREONINE KINASES; SIGNAL TRANSDUCTION;

EID: 84943792809     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2015.4288     Document Type: Review

References (79)

1. Resta N, Pierannunzio D, Lenato GM, Stella A, Capocaccia R, Bagnulo R, Lastella P, Susca FC, Bozzao C, Loconte DC, et al: Cancer risk associated with STK11/LKB1 germline mutations in Peutz-Jeghers syndrome patients: Results of an Italian multicenter study. Dig Liver Dis 45: 606-611, 2013.
2. Chen CY, Zhang XM, Wang FY, Wang ZK, Zhu M, Ma GJ, Zhang YY, Jin XX, Shi H and Liu J: Mutation screening of LKB1 gene in familial Peutz-Jeghers syndrome patients. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 29: 121-125, 2012 (In Chinese).
3. Fang R, Zheng C, Sun Y, Han X, Gao B, Li C, Liu H, Wong KK, Liu XY, Chen H, et al: Integrative genomic analysis reveals a high frequency of LKB1 genetic alteration in Chinese lung adenocarcinomas. J Thorac Oncol 9: 254-258, 2014.
4. Loi S, Michiels S, Lambrechts D, Fumagalli D, Claes B, Kellokumpu-Lehtinen PL, Bono P, Kataja V, Piccart MJ, Joensuu H, et al: Somatic mutation profiling and associations with prognosis and trastuzumab benefit in early breast cancer. J Natl Cancer Inst 105: 960-967, 2013.
5. Avizienyte E, Roth S, Loukola A, Hemminki A, Lothe RA, Stenwig AE, Fosså SD, Salovaara R and Aaltonen LA: Somatic mutations in LKB1 are rare in sporadic colorectal and testicular tumors. Cancer Res 58: 2087-2090, 1998.
6. Veleva-Rotse BO, Smart JL, Baas AF, Edmonds B, Zhao ZM, Brown A, Klug LR, Hansen K, Reilly G, Gardner AP, et al: STRAD pseudokinases regulate axogenesis and LKB1 stability. Neural Dev 9: 5, 2014.
7. Zeqiraj E, Filippi BM, Deak M, Alessi DR and van Aalten DM: Structure of the LKB1-STRAD-MO25 complex reveals an allosteric mechanism of kinase activation. Science 326: 1707-1711, 2009.
8. Mirouse V, Swick LL, Kazgan N, St Johnston D and Brenman JE: LKB1 and AMPK maintain epithelial cell polarity under energetic stress. J Cell Biol 203: 373, 2013.
9. Dahmani R, Just PA, Delay A, Canal F, Finzi L, Prip-Buus C, Lambert M, Sujobert P, Buchet-Poyau K, Miller E, et al: A novel LKB1 isoform enhances AMPK metabolic activity and displays oncogenic properties. Oncogene 34: 2337-2346, 2015.
10. Partanen JI, Tervonen TA and Klefström J: Breaking the epithelial polarity barrier in cancer: The strange case of LKB1/PAR-4. Philos Trans R Soc Lond BBiol Sci 368: 20130111, 2013.
11. Li J, Liu J, Li P, Mao X, Li W, Yang J and Liu P: Loss of LKB1 disrupts breast epithelial cell polarity and promotes breast cancer metastasis and invasion. J Exp Clin Cancer Res 33: 70, 2014.
12. Liang X, Wang P, Gao Q and Tao X: Exogenous activation of LKB1/AMPK signaling induces G1 arrest in cells with endogenous LKB1 expression. Mol Med Rep 9: 1019-1024, 2014.
13. Luo L, Huang W, Tao R, Hu N, Xiao ZX and Luo Z: ATM and LKB1 dependent activation of AMPK sensitizes cancer cells to etoposide-induced apoptosis. Cancer Lett 328: 114-119, 2013.
14. Hardie DG and Alessi DR: LKB1 and AMPK and the cancer-metabolism link-ten years after. BMC Biol 11: 36, 2013.
15. Gormand A, Henriksson E, Ström K, Jensen TE, Sakamoto K and Göransson O: Regulation of AMP-activated protein kinase by LKB1 and CaMKK in adipocytes. J Cell Biochem 112: 1364-1375, 2011.
16. Hardie DG: The LKB1-AMPK pathway-friend or foe in cancer? Cancer Cell 23: 131-132, 2013.
17. Hardie DG, Ross FA and Hawley SA: AMP-activated protein kinase: A target for drugs both ancient and modern. Chem Biol 19: 1222-1236, 2012.
18. Rena G, Pearson ER and Sakamoto K: Molecular mechanism of action of metformin: Old or new insights? Diabetologia 56: 1898-1906, 2013.
19. Mihaylova MM and Shaw RJ: The AMPK signalling pathway coordinates cell growth, autophagy and metabolism. Nat Cell Biol 13: 1016-1023, 2011.
20. Carling D, Mayer FV, Sanders MJ and Gamblin SJ: AMP-activated protein kinase: Nature's energy sensor. Nat Chem Biol 7: 512-518, 2011.
21. Lu J, Tan M and Cai Q: The Warburg effect in tumor progression: Mitochondrial oxidative metabolism as an anti-metastasis mechanism. Cancer Lett 356: 156-164, 2015.
22. Faubert B, Boily G, Izreig S, Griss T, Samborska B, Dong Z, Dupuy F, Chambers C, Fuerth BJ, Viollet B, et al: AMPK is a negative regulator of the Warburg effect and suppresses tumor growth in vivo. Cell Metab 17: 113-124, 2013.
23. Teng RJ, Du J, Afolayan AJ, Eis A, Shi Y and Konduri GG: AMP kinase activation improves angiogenesis in pulmonary artery endothelial cells with in utero pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 304: L29-L42, 2013.
24. Rattan R, Giri S, Singh AK and Singh I: 5-Aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside inhibits cancer cell proliferation in vitro and in vivo via AMP-activated protein kinase. J Biol Chem 280: 39582-39593, 2005.
25. van Veelen W, Korsse SE, van de Laar L and Peppelenbosch MP: The long and winding road to rational treatment of cancer associated with LKB1/AMPK/TSC/mTORC1 signaling. Oncogene 30: 2289-2303, 2011.
26. Dunlop EA and Tee AR: mTOR and autophagy: A dynamic relationship governed by nutrients and energy. Semin Cell Dev Biol 36: 121-129, 2014.
27. Jung CH, Ro SH, Cao J, Otto NM and Kim DH: mTOR regulation of autophagy. FEBS Lett 584: 1287-1295, 2010.
28. Shang L and Wang X: AMPK and mTOR coordinate the regulation of Ulk1 and mammalian autophagy initiation. Autophagy 7: 924-926, 2011.
29. Mack HI, Zheng B, Asara JM and Thomas SM: AMPK-dependent phosphorylation of ULK1 regulates ATG9 localization. Autophagy 8: 1197-1214, 2012.
30. Fenouille N, Tichet M, Dufies M, Pottier A, Mogha A, Soo JK, Rocchi S, Mallavialle A, Galibert MD, Khammari A, et al: The epithelial-mesenchymal transition (EMT) regulatory factor SLUG (SNAI2) is a downstream target of SPARC and AKT in promoting melanoma cell invasion. PLoS One 7: e40378, 2012.
31. Wong GS and Rustgi AK: Matricellular proteins: Priming the tumour microenvironment for cancer development and metastasis. Br J Cancer 108: 755-761, 2013.
32. Xiang X, Zhao X, Qu H, Li D, Yang D, Pu J, Mei H, Zhao J, Huang K, Zheng L, et al: Hepatocyte nuclear factor 4 alpha promotes the invasion, metastasis and angiogenesis of neuroblastoma cells via targeting matrix metalloproteinase 14. Cancer Lett 359: 187-197, 2015.
33. Magee PJ, Allsopp P, Samaletdin A and Rowland IR: Daidzein, R-(+)equol and S-(-)equol inhibit the invasion of MDA-MB-231 breast cancer cells potentially via the down-regulation of matrix metalloproteinase-2. Eur J Nutr 53: 345-350, 2014.
34. Merdad A, Karim S, Schulten HJ, Dallol A, Buhmeida A, Al-Thubaity F, Gari MA, Chaudhary AG, Abuzenadah AM and Al-Qahtani MH: Expression of matrix metalloproteinases (MMPs) in primary human breast cancer: MMP-9 as a potential biomarker for cancer invasion and metastasis. Anticancer Res 34: 1355-1366, 2014.
35. Jiang H, Gao M, Shen Z, Luo B, Li R, Jiang X, Ding R, Ha Y, Wang Z and Jie W: Blocking PI3K/Akt signaling attenuates metastasis of nasopharyngeal carcinoma cells through induction of mesenchymal-epithelial reverting transition. Oncol Rep 32: 559-566, 2014.
36. Son H and Moon A: Epithelial-mesenchymal transition and cell invasion. Toxicol Res 26: 245-252, 2010.
37. Wang Y and Zhou BP: Epithelial-mesenchymal transition in breast cancer progression and metastasis. Chin J Cancer 30: 603-611, 2011.
38. May CD, Sphyris N, Evans KW, Werden SJ, Guo W and Mani SA: Epithelial-mesenchymal transition and cancer stem cells: A dangerously dynamic duo in breast cancer progression. Breast Cancer Res 13: 202, 2011.
39. Xu J, Lamouille S and Derynck R: TGF-beta-induced epithelial to mesenchymal transition. Cell Res 19: 156-172, 2009.
40. Weiss A and Attisano L: The TGFbeta superfamily signaling pathway. Wiley Interdiscip Rev Dev Biol 2: 47-63, 2013.
41. Katsuno Y, Lamouille S and Derynck R: TGF-β signaling and epithelial-mesenchymal transition in cancer progression. Curr Opin Oncol 25: 76-84, 2013.
42. Porsch H, Bernert B, Mehić M, Theocharis AD, Heldin CH and Heldin P: Efficient TGFβ-induced epithelial-mesenchymal transition depends on hyaluronan synthase HAS2. Oncogene 32: 4355-4365, 2013.
43. Wiercinska E, Naber HP, Pardali E, van der Pluijm G, van Dam H and ten Dijke P: The TGF-β/Smad pathway induces breast cancer cell invasion through the up-regulation of matrix metalloproteinase 2 and 9 in a spheroid invasion model system. Breast Cancer Res Treat 128: 657-666, 2011.
44. Lamouille S and Derynck R: Cell size and invasion in TGF-beta-induced epithelial to mesenchymal transition is regulated by activation of the mTOR pathway. J Cell Biol 178: 437-451, 2007.
45. Lamouille S, Connolly E, Smyth JW, Akhurst RJ and Derynck R: TGF-β-induced activation of mTOR complex 2 drives epithelial-mesenchymal transition and cell invasion. J Cell Sci 125: 1259-1273, 2012.
46. Thakur N, Gudey SK, Marcusson A, Fu JY, Bergh A, Heldin CH and Landström M: TGFβ-induced invasion of prostate cancer cells is promoted by c-Jun-dependent transcriptional activation of Snail1. Cell Cycle 13: 2400-2414, 2014.
47. Saini KS, Loi S, de Azambuja E, Metzger-Filho O, Saini ML, Ignatiadis M, Dancey JE and Piccart-Gebhart MJ: Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer. Cancer Treat Rev 39: 935-946, 2013.
48. Yeh CB, Hsieh MJ, Hsieh YH, Chien MH, Chiou HL and Yang SF: Antimetastatic effects of norcantharidin on hepatocellular carcinoma by transcriptional inhibition of MMP-9 through modulation of NF-κB activity. PLoS One 7: e31055, 2012.
49. Zhang W, Liu Y and Wang CW: S100A4 promotes squamous cell laryngeal cancer Hep-2 cell invasion via NF-κB/MMP-9 signal. Eur Rev Med Pharmacol Sci 18: 1361-1367, 2014.
50. Lu JT, Zhao WD, He W and Wei W: Hedgehog signaling pathway mediates invasion and metastasis of hepatocellular carcinoma via ERK pathway. Acta Pharmacol Sin 33: 691-700, 2012.
51. Setia S, Nehru B and Sanyal SN: Upregulation of MAPK/Erk and PI3K/Akt pathways in ulcerative colitis-associated colon cancer. Biomed Pharmacother 68: 1023-1029, 2014.
52. Arechederra M, Priego N, Vázquez-Carballo A, Sequera C, Gutiérrez-Uzquiza Á, Cerezo-Guisado MI, Ortiz-Rivero S, Roncero C, Cuenda A, Guerrero C, et al: p38 MAPK down-regulates fibulin 3 expression through methylation of gene regulatory sequences: Role in migration and invasion. J Biol Chem 290: 4383-4397, 2015.
53. Chen X, Meng J, Yue W, Yu J, Yang J, Yao Z and Zhang L: Fibulin-3 suppresses Wnt/β-catenin signaling and lung cancer invasion. Carcinogenesis 35: 1707-1716, 2014.
54. Liu Z, Rebowe RE, Wang Z, Li Y, Wang Z, DePaolo JS, Guo J, Qian C and Liu W: KIF3a promotes proliferation and invasion via Wnt signaling in advanced prostate cancer. Mol Cancer Res 12: 491-503, 2014.
55. Wu HT, Sie SS, Kuan TC and Lin CS: Identifying the regulative role of NF-κB binding sites within promoter region of human matrix metalloproteinase 9 (mmp-9) by TNF-α induction. Appl Biochem Biotechnol 169: 438-449, 2013.
56. Oue T, Uehara S, Yamanaka H, Nomura M and Usui N: Hedgehog signal inhibitors suppress the invasion of human rhabdomyosarcoma cells. Pediatr Surg Int 29: 1153-1158, 2013.
57. Goodwin JM, Svensson RU, Lou HJ, Winslow MM, Turk BE and Shaw RJ: An AMPK-independent signaling pathway downstream of the LKB1 tumor suppressor controls Snail1 and metastatic potential. Mol Cell 55: 436-450, 2014.
58. Roy BC, Kohno T, Iwakawa R, Moriguchi T, Kiyono T, Morishita K, Sanchez-Cespedes M, Akiyama T and Yokota J: Involvement of LKB1 in epithelial-mesenchymal transition (EMT) of human lung cancer cells. Lung Cancer 70: 136-145, 2010.
59. Shorning BY, Griffiths D and Clarke AR: Lkb1 and Pten synergise to suppress mTOR-mediated tumorigenesis and epithelial-mesenchymal transition in the mouse bladder. PLoS One 6: e16209, 2011.
60. Kim EK, Park JM, Lim S, Choi JW, Kim HS, Seok H, Seo JK, Oh K, Lee DS, Kim KT, et al: Activation of AMP-activated protein kinase is essential for lysophosphatidic acid-induced cell migration in ovarian cancer cells. J Biol Chem 286: 24036-24045, 2011.
61. Cerezo M, Tichet M, Abbe P, Ohanna M, Lehraiki A, Rouaud F, Allegra M, Giacchero D, Bahadoran P, Bertolotto C, et al: Metformin blocks melanoma invasion and metastasis development in AMPK/p53-dependent manner. Mol Cancer Ther 12: 1605-1615, 2013.
62. Esfahanian N, Shakiba Y, Nikbin B, Soraya H, Maleki-Dizaji N, Ghazi-Khansari M and Garjani A: Effect of metformin on the proliferation, migration, and MMP-2 and-9 expression of human umbilical vein endothelial cells. Mol Med Rep 5: 1068-1074, 2012.
63. Hsu CJ, Wu MH, Chen CY, Tsai CH, Hsu HC and Tang CH: AMP-activated protein kinase activation mediates CCL3-induced cell migration and matrix metalloproteinase-2 expression in human chondrosarcoma. Cell Commun Signal 11: 68, 2013.
64. Kim HS, Kim MJ, Kim EJ, Yang Y, Lee MS and Lim JS: Berberine-induced AMPK activation inhibits the metastatic potential of melanoma cells via reduction of ERK activity and COX-2 protein expression. Biochem Pharmacol 83: 385-394, 2012.
65. Chou CC, Lee KH, Lai IL, Wang D, Mo X, Kulp SK, Shapiro CL and Chen CS: AMPK reverses the mesenchymal phenotype of cancer cells by targeting the Akt-MDM2-Foxo3a signaling axis. Cancer Res 74: 4783-4795, 2014.
66. Choudhury Y, Yang Z, Ahmad I, Nixon C, Salt IP and Leung HY: AMP-activated protein kinase (AMPK) as a potential therapeutic target independent of PI3K/Akt signaling in prostate cancer. Oncoscience 1: 446-456, 2014.
67. Petursson F, Husa M, June R, Lotz M, Terkeltaub R and Liu-Bryan R: Linked decreases in liver kinase B1 and AMP-activated protein kinase activity modulate matrix catabolic responses to biomechanical injury in chondrocytes. Arthritis Res Ther 15: R77, 2013.
68. Ramnanan CJ, McMullen DC, Groom AG and Storey KB: The regulation of AMPK signaling in a natural state of profound metabolic rate depression. Mol Cell Biochem 335: 91-105, 2010.
69. Lee JH, Kim JH, Kim JS, Chang JW, Kim SB, Park JS and Lee SK: AMP-activated protein kinase inhibits TGF-β-, angiotensin II-, aldosterone-, high glucose-, and albumin-induced epithelial-mesenchymal transition. Am J Physiol Renal Physiol 304: F686-F697, 2013.
70. Lim JY, Oh MA, Kim WH, Sohn HY and Park SI: AMP-activated protein kinase inhibits TGF-β-induced fibrogenic responses of hepatic stellate cells by targeting transcriptional coactivator p300. J Cell Physiol 227: 1081-1089, 2012.
71. Goncharova EA, Goncharov DA, James ML, Atochina-Vasserman EN, Stepanova V, Hong SB, Li H, Gonzales L, Baba M, Linehan WM, et al: Folliculin controls lung alveolar enlargement and epithelial cell survival through E-cadherin, LKB1, and AMPK. Cell Reports 7: 412-423, 2014.
72. Zhou J, Yang Z, Tsuji T, Gong J, Xie J, Chen C, Li W, Amar S and Luo Z: LITAF and TNFSF15, two downstream targets of AMPK, exert inhibitory effects on tumor growth. Oncogene 30: 1892-1900, 2011.
73. Queiroz EA, Puukila S, Eichler R, Sampaio SC, Forsyth HL, Lees SJ, Barbosa AM, Dekker RF, Fortes ZB and Khaper N: Metformin induces apoptosis and cell cycle arrest mediated by oxidative stress, AMPK and FOXO3a in MCF-7 breast cancer cells. PLoS One 9: e98207, 2014.
74. Zhou J, Huang W, Tao R, Ibaragi S, Lan F, Ido Y, Wu X, Alekseyev YO, Lenburg ME, Hu GF, et al: Inactivation of AMPK alters gene expression and promotes growth of prostate cancer cells. Oncogene 28: 1993-2002, 2009.
75. Lee GR, Jang SH, Kim CJ, Kim AR, Yoon DJ, Park NH and Han IS: Capsaicin suppresses the migration of cholangiocarcinoma cells by down-regulating matrix metalloproteinase-9 expression via the AMPK-NF-κB signaling pathway. Clin Exp Metastasis 31: 897-907, 2014.
76. Wu X, Yan Q, Zhang Z, Du G and Wan X: Acrp30 inhibits leptin-induced metastasis by downregulating the JAK/STAT3 pathway via AMPK activation in aggressive SPEC-2 endometrial cancer cells. Oncol Rep 27: 1488-1496, 2012.
77. Park SY, Lee YK, Lee WS, Park OJ and Kim YM: The involvement of AMPK/GSK3-beta signals in the control of metastasis and proliferation in hepato-carcinoma cells treated with anthocyanins extracted from Korea wild berry Meoru. BMC Complement Altern Med 14: 109, 2014.
78. Suzuki A, Lu J, Kusakai G, Kishimoto A, Ogura T and Esumi H: ARK5 is a tumor invasion-associated factor downstream of Akt signaling. Mol Cell Biol 24: 3526-3535, 2004.
79. Chen P, Li K, Liang Y, Li L and Zhu X: High NUAK1 expression correlates with poor prognosis and involved in NSCLC cells migration and invasion. Exp Lung Res 39: 9-17, 2013.